Venn Life Sciences Holdings PLC Posting of Annual Report and Notice of AGM (8710A)
10 Juin 2016 - 12:05PM
UK Regulatory
TIDMVENN
RNS Number : 8710A
Venn Life Sciences Holdings PLC
10 June 2016
10 June 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Posting of Annual Report & Notice of AGM
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing a suite of consulting and clinical
trial services to pharmaceutical, biotechnology and medical device
clients, confirms that the Annual Report and Accounts for the year
ended 31 December 2015 ("2015 Annual Report and Accounts"), the
Notice of the Annual General Meeting ("AGM") and a Form of Proxy
have been posted to shareholders.
The AGM is to be held at 11am on 30 June 2016 at Finsgate, 5-7
Cranwood Street, London EC1 V9EE.
A copy of the 2015 Annual Report and Accounts and other
documents are available on the Company's website:
http://vennlifesciences.com/
Enquiries:
Venn Life Sciences Holdings www.vennlifesciences.com
Plc
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Jonathan Hartshorn, Chief Financial Tel: +353 153 93 269
Officer
Orla McGuinness, Marketing Tel: +353 153 93 269
Manager
Davy (Nominated Adviser, ESM Tel: +353 1 679 6363
Adviser and Joint Broker)
Fergal Meegan / Matthew DeVere
White (Corporate Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint-Broker)
Claire Louise Noyce Tel: 020 3764 2341
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a
Contract Research Organisation providing drug development, clinical
trial management and resourcing solutions to pharmaceutical,
biotechnology and medical device organisations. With dedicated
operations in France, Germany, the Netherlands, the UK, Ireland and
Europe wide representation - Venn Life Sciences specialises in
rapid deployment and management of multisite projects, across all
phases. Venn Life Sciences also has an innovation division -
Innovenn - focused primarily on breakthrough development
opportunities in Skin Science.
For more information about the Company, please visit:
www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMMMTMBMBBTF
(END) Dow Jones Newswires
June 10, 2016 06:05 ET (10:05 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024